TRS

TriMas is mid-transformation, and that — not the headline numbers — drives the call. The 10-K discloses a Nov 2025 agreement to sell TriMas Aerospace to a Tinicum/Blackstone affiliate for ~$1.45B cash, expected to close Q1 2026, with Aerospace already reclassified to assets held for sale / discontinued operations. Against a $1.68B market cap, that incoming cash is roughly 86% of the equity value, and management has the balance sheet flexibility to pay down all $473M of long-term debt and still return a large sum — they already repurchased $103M of stock in FY2025, shrinking the share count 7.2%. That optionality is the bull case.

The problem is that the continuing business left behind is only mediocre, and the reported earnings flatter it. FY2025 revenue grew just 2.4% to $646M, with Packaging organic growth of +4.1% partly offset by Specialty Products down 7.0% as Norris Cylinder demand softened into a destocking cycle and China-sourced products absorbed new tariff costs. Crucially, net income jumped +395% to $120M and EPS +392% to $2.95 while operating income was only $41.3M — a net result nearly 3x operating income. MD&A attributes the gap largely to a non-recurring asbestos insurance-recovery benefit and the Arrow Engine divestiture gain, so the optically reasonable 15.1x P/E sits on inflated EPS; the true continuing-operations earnings power on a 6.4% operating margin is far thinner, and the real multiple is materially higher.